Reduced liver transplants
First, I need to recall what "reduced liver transplants" refer to. I think it's about living donor liver transplants where a portion of the donor's liver is used. The donor's liver is split into left or right lobes for the recipient. So maybe the question is about indications, contraindications, or complications.
The correct answer is probably related to a contraindication for living donor liver transplants. Let me think of common contraindications. Absolute contraindications include active malignancy, severe coagulopathy, or uncontrolled infections. Relative contraindications might be obesity or certain medical conditions.
If the options are about contraindications, then the correct answer would be something like "Active malignancy in the donor". The other options could be things like donor age over 60 (relative), donor BMI >35 (relative), or recipient's HCV (not a donor contraindication).
Wait, the question is about reduced liver transplants, which are typically from living donors. So the answer likely relates to donor contraindications. Let me structure the explanation accordingly. The core concept is living donor liver transplantation and its contraindications. The correct answer would be an absolute contraindication. The incorrect options would be relative or not applicable.
I need to make sure the explanation is clear and covers the key points. The clinical pearl should highlight the absolute vs. relative contraindications. Also, mention the importance of donor safety. Alright, putting it all together now.
**Core Concept**
Reduced liver transplants refer to living donor liver transplants (LDLT) where a portion of the donor’s liver is transplanted into the recipient. Absolute contraindications for LDLT include donor-related factors that pose unacceptable risk to the donor or recipient, such as active malignancy or severe coagulopathy.
**Why the Correct Answer is Right**
**Option C: Active malignancy in the donor** is correct because active cancer in the donor is an absolute contraindication. Malignancy increases the risk of tumor recurrence post-transplant and compromises donor safety. The donor’s liver must be free of malignancy to ensure both donor health and graft viability.
**Why Each Wrong Option is Incorrect**
**Option A: Recipient’s chronic hepatitis C** – This is a recipient-related factor, not a donor contraindication. HCV can be managed post-transplant with antiviral therapy.
**Option B: Donor age >60 years** – This is a relative contraindication, not an absolute one. Older donors may still be suitable if they have good liver function and no comorbidities.
**Option D: Donor BMI >35 kg/m²** – Obesity is a relative contraindication due to increased surgical risk, but not an absolute bar. Careful evaluation is required.
**Clinical Pearl / High-Yield Fact**
Remember the **"3 A’s" of LDLT contraindications**: **Active malignancy**,